Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (70)	2/11/2000 10:23:00 PM
From: margie	Read Replies (2) \| Respond to of 1833

Next feature on 20/20 now, is about this new drug. abcnews.go.com ABC about 10:15 PM EST. The Miracle Pill New Leukemia Treatment a ?Home Run? A chance encounter with a report about studies of a new pill has given Gerry Best, center, new hope in his battle against leukemia. (ABCNEWS.com) Sorry, wrong thread, but I thought it might be noticed in time for those on the East Coast.

To: scaram(o)uche who wrote (70)	2/11/2000 10:37:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

J Am Coll Cardiol 2000 Jan;35(1):56-9 Related Articles, Books Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA. sgottlie@medicine.umaryland.edu OBJECTIVES: To determine the effects of furosemide and the selective A1 adenosine receptor BG9719 on renal function in patients with congestive heart failure (CHF). BACKGROUND: Studies suggest that adenosine may affect renal function by various mechanisms, but the effects of blockade of this system in humans is unknown. In addition, the effects of a therapeutic dose of furosemide on glomerular filtration rate (GFR) and renal plasma flow (RPF) in heart failure patients are controversial. METHODS: On different days, 12 patients received placebo, BG9719 and furosemide. Glomerular filtration rate, RPF and sodium and water excretion were assessed immediately following drug administration. RESULTS: Glomerular filtration rate was 84 +/- 23 ml/min/1.73m2 after receiving placebo, 82 +/- 24 following BG9719 administration and a decreased (p < 0.005) 63 +/- 18 following furosemide. Renal plasma flow was unchanged at 293 +/- 124 ml/min/1.73m2 on placebo, 334 +/- 155 after receiving BG9719 and 374 +/- 231 after receiving furosemide. Sodium excretion increased from 8 +/- 8 mEq following placebo administration to 37 +/- 26 mEq following BG9719 administration. In the six patients in whom it was measured, sodium excretion was 104 +/- 78 mEq following furosemide administration. CONCLUSIONS: Natriuresis is effectively induced by both furosemide and the adenosine A1 antagonist BG9719 in patients with CHF. Doses of the two drugs used in this study did not cause equivalent sodium and water excretion but only furosemide decreased GFR. These data suggest that adenosine is an important determinant of renal function in patients with heart failure.